{"adverse_reactions":["6. ADVERSE REACTIONS 6.1. The most common mild adverse reaction is slight reddening at the injection site due to the mechanical effect of the needle or a superficial skin reaction of mild erythema."],"clinical_pharmacology":["12. CLINICAL PHARMACOLOGY 12.1. Mechanism of Action The medication acts through a low-dose enzymatic mechanism. 12.2. Pharmacodynamics The physiological effects of OMEOFORMULA®2- CELLULITE are due to the effects of the ingredients, according to their description in the Homeopathic Materia Medica. 12.3. Pharmacokinetics Homeopathic attenuation provides complete bioavability of the active ingredients."],"clinical_studies":["14. CLINICAL STUDIES 14.1. OMEOFORMULA®2-CELLULITE formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic proving as refer in Materia Medica."],"contraindications":["4. CONTRAINDICATIONS 4.1. There is no history of hypersensitivity to OMEOFORMULA®2-CELLULITE. However patients with a known hypersensitivity to any ingredient should be tested before use. Make a spot injection (0.1ml) into the forearm and observe for any reactions for 1 hour."],"description":["11. DESCRIPTION OMEOFORMULA®2- CELLULITE is a sterile solution made with isotonic sodium chloride solution. Its formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic proving as refer in Materia Medica. Aranea diadema and Natrum sulfuricum promote reduction in edema limiting water retention. Myosotis arvensis, Lymphatic vessels, Scrophularia nodosa, and Juglans regia promote edema reduction by facilitating lymphatic drainage. Vein and Hamamelis improve venous return. Calcium sulphuricum and Graphites reduce cellulite accumulation on the lateral thighs, while Calcium phosphoricum reduces cellulite accumulation at the root of the thigh. Krebs cycle intermediates support cell metabolism. Echinacea angustifolia protects the epithelial cells against stretch marks."],"dosage_and_administration":["2. DOSAGE AND ADMINISTRATION 2.1. Treatment of total body adiposity for IM application: 1 vial 1-3 times a week according to severity and clinic evolution. 2.2. Treatment of localized adiposity using mesotherapy technique: Apply 0,3 ml for each point. Using a 13 mm, 30G or a 4 mm, 27G needle, make the classic intradermal injections utilizing mesotherapy technique. Application points: Apply to Affected area (saddlebags, root of the thigh, knees, and arms) and/or at acupuncture points. Standard protocol consists of one treatment a week for 5-7 weeks. For prolonged treatments, 2 treatments for the first week, 1 session a week for 1 month and then 1 treatment a month are recommended. Discard unused solution. 2.3. Opening of Vials: Use sterile needles and sterile syringe. Do not reuse. Do not use if foreign particles are present. Draw 1 cc of air into syringe, insert needle into vial inject air and withdraw the solution into the syringe."],"dosage_forms_and_strengths":["3. DOSAGE FORMS AND STRENGTHS 3.1. Injectable solution for subcutaneneous, intradermal, or intramuscular administration. Pharmaceutical forms: 2 ml glass vials. 3.2. Each ingredient is attenuated according to the procedures stated in the Homeopathic Pharmacopeia of United States. Active ingredients : a-Ketoglutaricum acidum 6X; Adenosinum cyclophosphoricum 6X; Aranea diadema 10X; Barium oxalosuccinate 6X; Calcarea phosphorica 6X; Calcarea phosphorica 30X; Calcarea phosphorica 200X; Calcarea sulphurica 6X; Calcarea sulphurica 30X; Calcarea sulphurica 200X; Cis-Aconitic acid 6X; Citricum acidum 6X; Dl malic acid 6X; Echinacea angustifolia 10X; Fumaricum acidum 6X; Graphites 10X; Hamamelis virginiana 10X; Juglans regia 6X; Lymphatic vessel 6X; Magnesium gluconate 6X; Manganum phosphoricum 6X; Myosotis arvensis 6X; Natrum pyruvicum 6X; Natrum sulphuricum 6X; Nicotinamidum 6X; Scrophularia nodosa 6X; Succinicum acidum 6X; Vein 10X. Inactive ingredient : Sterile isotonic sodium chloride solution."],"drug_abuse_and_dependence":["9. DRUG ABUSE AND DEPENDENCE 9.1. No Known."],"drug_interactions":["7. DRUG INTERACTIONS 7.1. None Known."],"effective_time":"20110626","id":"f36aa3cc-bafe-4ee4-9687-75c779be7a71","indications_and_usage":["1. INDICATIONS AND USAGE 1.1. Treatment total body adiposity 1.2. Treatment of localized adiposity It is helpful to combine the treatment with appropriate dietary modifications."],"information_for_patients":["17. PATIENT COUNSELING INFORMATION 17.1. Patients should be informed of the homeopathic approach and OMEOFORMULA®2- CELLULITE therapeutic goals."],"nonclinical_toxicology":["13. NONCLINICAL TOXICOLOGY 13.1. OMEOFORMULA®2- CELLULITE has no level of toxicity due to the attenuation of the ingredients."],"openfda":{},"overdosage":["10. OVERDOSAGE 10.1. No Known."],"package_label_principal_display_panel":["PACKAGE LABEL image of box label"],"references":["15. REFERENCES 15.1. E.Italia, M. De Bellis: Manuale di Omeo-mesoterapia – Guna Ed. 1995. 15.2. H.H. Reckeweg: Homeopathic Materia medica. Aurelia Verlag."],"set_id":"a108a36e-bc70-47c7-9fd7-41fde8be99ed","spl_product_data_elements":["OMEOFORMULA2-CELLULITE .ALPHA.-KETOGLUTARIC ACID - ACONITIC ACID, CIS - ARANEUS DIADEMATUS - BARIUM CATION - CALCIUM PHOSPHATE - CITRIC ACID MONOHYDRATE - CYCLIC AMP - ECHINACEA ANGUSTIFOLIA - FUMARIC ACID - GRAPHITE - JUGLANS REGIA LEAF - MAGNESIUM GLUCONATE - MALIC ACID - MANGANESE PHOSPHATE, DIBASIC - MYOSOTIS ARVENSIS - NATRUM SULPHURICUM - NIACINAMIDE - SCROPHULARIA NODOSA - SODIUM PYRUVATE - SUCCINIC ACID - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA VEIN - ADENOSINE CYCLIC 3',5'-PHOSPHATE ADENOSINE CYCLIC 3',5'-PHOSPHATE .ALPHA.-KETOGLUTARIC ACID .ALPHA.-KETOGLUTARIC ACID ARANEUS DIADEMATUS ARANEUS DIADEMATUS BARIUM OXALOSUCCINATE BARIUM OXALOSUCCINATE CALCIUM PHOSPHATE CALCIUM CATION CALCIUM SULFATE ANHYDROUS CALCIUM CATION ACONITIC ACID, (Z)- ACONITIC ACID, (Z)- CITRIC ACID MONOHYDRATE ANHYDROUS CITRIC ACID MALIC ACID MALIC ACID ECHINACEA ANGUSTIFOLIA ECHINACEA ANGUSTIFOLIA FUMARIC ACID FUMARIC ACID GRAPHITE GRAPHITE HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK JUGLANS REGIA LEAF JUGLANS REGIA LEAF SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE MAGNESIUM GLUCONATE MAGNESIUM CATION MANGANESE PHOSPHATE, DIBASIC MANGANESE PHOSPHATE, DIBASIC MYOSOTIS ARVENSIS MYOSOTIS ARVENSIS SODIUM PYRUVATE PYRUVIC ACID SODIUM SULFATE SODIUM CATION NIACINAMIDE NIACINAMIDE SCROPHULARIA NODOSA SCROPHULARIA NODOSA SUCCINIC ACID SUCCINIC ACID SUS SCROFA VEIN SUS SCROFA VEIN SODIUM CHLORIDE WATER"],"storage_and_handling":["16. HOW SUPPLIED/STORAGE AND HANDLING 16.1. NDC 17089-273-31 10 glass vials packed in carton box 16.2. NDC 17089-273-32 50 glass vials packed in carton box 16.3. Store at room temperature, 20-25°C (68-77° F). Avoid freezing and excessive heat."],"use_in_specific_populations":["8. USE IN SPECIFIC POPULATIONS 8.1 Pregnancy : Pregnancy category C. Animal reproduction studies have not been conducted with OMEOFORMULA®2-CELLULITE. OMEOFORMULA®2-CELLULITE should not be administered to a pregnant woman. 8.2 Nursing mothers : It is not known whether any of the ingredients in OMEOFORMULA®2-CELLULITE are secreted in human milk. However, since many drugs are secreted in human milk, caution should be exercised when OMEOFORMULA®2-CELLULITE is administered to a nursing woman. 8.3 Pediatric use : Effectiveness in pediatric patients has not been established. 8.4 Geriatric use : No restrictions."],"version":"2","warnings_and_cautions":["5. WARNINGS AND PRECAUTIONS 5.1. Be sure to disinfect the area before application. Skin disinfection helps avoid infection at the site of administration that can result from saprophytic bacteria (i.e. atypical mycobacteria, staphylococcus genus) that may be present on the skin. 5.2. Skin disinfection is required before application. Saprophytic bacteria may produce injection site abscesses with improper skin preparation."]}